Spots Global Cancer Trial Database for talimogene laherparepvec
Every month we try and update this database with for talimogene laherparepvec cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | NCT03714828 | Squamous Cell C... Skin Cancer Keratoacanthoma Cutaneous Tumor Skin Cancer, Sq... Lesion Skin | Injection of TV... Injection of TV... Injection of TV... Injection of TV... | 18 Years - | University of Arizona | |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | NCT02658812 | Malignant Chest... Recurrent Breas... Recurrent Infla... Stage IV Breast... Stage IV Inflam... | Laboratory Biom... Talimogene Lahe... | 18 Years - | M.D. Anderson Cancer Center | |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | NCT03300544 | Locally Advance... Metastatic Rect... Rectal Adenocar... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IV Rectal... Stage IVA Recta... Stage IVB Recta... | Capecitabine Fluorouracil Leucovorin Oxaliplatin Radiation Thera... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | NCT00402025 | Pancreatic Canc... | Talimogene Lahe... | 18 Years - | BioVex Limited | |
| Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | NCT00769704 | Melanoma | Talimogene lahe... GM-CSF | 18 Years - | BioVex Limited | |
| Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | NCT03802604 | Breast Cancer | Talimogene lahe... Atezolizumab | 18 Years - 99 Years | SOLTI Breast Cancer Research Group | |
| Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma | NCT02147951 | Unresected Stag... | Talimogene Lahe... | 18 Years - 95 Years | Amgen | |
| Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | NCT02014441 | Melanoma | Talimogene lahe... | 18 Years - 100 Years | Amgen | |
| Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | NCT02366195 | Unresected Stag... | Talimogene Lahe... | 18 Years - | Amgen | |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | NCT02965716 | Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Pembrolizumab Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | NCT01161498 | Squamous Cell C... Head and Neck C... | Talimogene Lahe... Radiation Cisplatin | 18 Years - | BioVex Limited | |
| Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | NCT02211131 | Completely Rese... | Talimogene Lahe... Immediate surgi... | 18 Years - | Amgen | |
| An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | NCT01368276 | Melanoma | Talimogene Lahe... Granulocyte Mac... | 18 Years - | BioVex Limited | |
| Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | NCT02014441 | Melanoma | Talimogene lahe... | 18 Years - 100 Years | Amgen | |
| A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | NCT03597009 | Malignant Pleur... Stage IV Metast... Lung Cancer | Talimogene lahe... Nivolumab | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies | NCT03663712 | Stage IV Perito... | Talimogene Lahe... | 18 Years - 99 Years | Duke University | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | NCT00402025 | Pancreatic Canc... | Talimogene Lahe... | 18 Years - | BioVex Limited | |
| Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | NCT02297529 | Unresected Stag... | Talimogene Lahe... | 18 Years - 95 Years | Amgen | |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | NCT00402025 | Pancreatic Canc... | Talimogene Lahe... | 18 Years - | BioVex Limited | |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | NCT03256344 | Metastatic Trip... Metastatic Colo... | Talimogene Lahe... Atezolizumab | 18 Years - 99 Years | Amgen | |
| Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | NCT02509507 | Hepatocellular ... Liver Metastase... Cutaneous or Su... Liver Tumors | Talimogene Lahe... Pembrolizumab | 18 Years - | Amgen | |
| Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | NCT00769704 | Melanoma | Talimogene lahe... GM-CSF | 18 Years - | BioVex Limited | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | NCT03086642 | Pancreatic Canc... | Talimogene lahe... | 18 Years - | Columbia University | |
| Registry Study for Talimogene Laherparepvec | NCT02173171 | Any Tumor Type ... | Information col... | 18 Years - 99 Years | Amgen | |
| Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | NCT00769704 | Melanoma | Talimogene lahe... GM-CSF | 18 Years - | BioVex Limited | |
| Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma | NCT04065152 | Kaposi Sarcoma | Talimogene lahe... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma | NCT03842943 | Cutaneous Melan... | Pembrolizumab Talimogene Lahe... | 18 Years - | University of Louisville | |
| An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | NCT02574260 | Melanoma | Talimogene Lahe... | 18 Years - | BioVex Limited | |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | NCT04163952 | Locally Advance... Metastatic Skin... Recurrent Skin ... | Panitumumab Talimogene Lahe... | 18 Years - | Rutgers, The State University of New Jersey | |
| Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection | NCT02910557 | Melanoma Herpetic Infect... | - | Amgen | ||
| Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | NCT02297529 | Unresected Stag... | Talimogene Lahe... | 18 Years - 95 Years | Amgen | |
| Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | NCT02756845 | Advanced Non CN... | Talimogene Lahe... | 2 Years - 21 Years | Amgen | |
| Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | NCT03802604 | Breast Cancer | Talimogene lahe... Atezolizumab | 18 Years - 99 Years | SOLTI Breast Cancer Research Group | |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | NCT01740297 | Melanoma | Talimogene lahe... Ipilimumab | 18 Years - | Amgen | |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | NCT04068181 | Melanoma | Talimogene lahe... Pembrolizumab | 18 Years - 99 Years | Amgen | |
| Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | NCT02297529 | Unresected Stag... | Talimogene Lahe... | 18 Years - 95 Years | Amgen | |
| TVEC and Preop Radiation for Sarcoma (8 ml Dose) | NCT04599062 | Soft Tissue Sar... | Talimogene Lahe... Radiotherapy | 18 Years - | University of Iowa | |
| Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | NCT03086642 | Pancreatic Canc... | Talimogene lahe... | 18 Years - | Columbia University | |
| TVEC and Preop Radiation for Sarcoma (8 ml Dose) | NCT04599062 | Soft Tissue Sar... | Talimogene Lahe... Radiotherapy | 18 Years - | University of Iowa | |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma | NCT03842943 | Cutaneous Melan... | Pembrolizumab Talimogene Lahe... | 18 Years - | University of Louisville | |
| A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | NCT00289016 | Melanoma | Talimogene Lahe... | 18 Years - | BioVex Limited | |
| Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | NCT01161498 | Squamous Cell C... Head and Neck C... | Talimogene Lahe... Radiation Cisplatin | 18 Years - | BioVex Limited | |
| Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | NCT03802604 | Breast Cancer | Talimogene lahe... Atezolizumab | 18 Years - 99 Years | SOLTI Breast Cancer Research Group | |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | NCT03256344 | Metastatic Trip... Metastatic Colo... | Talimogene Lahe... Atezolizumab | 18 Years - 99 Years | Amgen | |
| TVEC and Preop Radiation for Sarcoma (4 ml Dose) | NCT02453191 | Soft Tissue Sar... | Talimogene Lahe... Radiotherapy | 18 Years - | University of Iowa | |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | NCT02923778 | Leiomyosarcoma Liposarcoma Sarcoma G2 Sarcoma G3 Soft Tissue Sar... Soft Tissue Sar... Stage I Soft Ti... Stage II Soft T... Undifferentiate... | Biopsy Biospecimen Col... Magnetic Resona... Radiation Thera... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | NCT04068181 | Melanoma | Talimogene lahe... Pembrolizumab | 18 Years - 99 Years | Amgen | |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | NCT03300544 | Locally Advance... Metastatic Rect... Rectal Adenocar... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IV Rectal... Stage IVA Recta... Stage IVB Recta... | Capecitabine Fluorouracil Leucovorin Oxaliplatin Radiation Thera... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | NCT02366195 | Unresected Stag... | Talimogene Lahe... | 18 Years - | Amgen | |
| Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) | NCT02626000 | Carcinoma of th... | Talimogene Lahe... Pembrolizumab | 18 Years - | Amgen | |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | NCT02965716 | Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Pembrolizumab Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | NCT02263508 | Melanoma | Talimogene Lahe... Pembrolizumab Placebo | 18 Years - 95 Years | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
